[go: up one dir, main page]

HRP20050744A2 - 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis - Google Patents

4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Info

Publication number
HRP20050744A2
HRP20050744A2 HR20050744A HRP20050744A HRP20050744A2 HR P20050744 A2 HRP20050744 A2 HR P20050744A2 HR 20050744 A HR20050744 A HR 20050744A HR P20050744 A HRP20050744 A HR P20050744A HR P20050744 A2 HRP20050744 A2 HR P20050744A2
Authority
HR
Croatia
Prior art keywords
ylmethoxy
oxazol
cyclohexyloxy
atherosclerosis
phenyl
Prior art date
Application number
HR20050744A
Other languages
English (en)
Croatian (hr)
Inventor
Stapper Christian
Keil Stefanie
Glombik Heiner
Falk Eugen
Goerlitzer Jochen
Gretzke Dirk
Schaefer Hans-Ludwig
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050744A2 publication Critical patent/HRP20050744A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HR20050744A 2003-02-27 2004-02-19 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis HRP20050744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
HRP20050744A2 true HRP20050744A2 (en) 2006-09-30

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050742A HRP20050742A2 (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2004-02-19 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
HR20050743A HRP20050743A2 (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20050742A HRP20050742A2 (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Country Status (34)

Country Link
US (5) US7365084B2 (pl)
EP (3) EP1599453B1 (pl)
JP (3) JP2006519193A (pl)
KR (3) KR20050105492A (pl)
CN (3) CN100398526C (pl)
AR (3) AR043427A1 (pl)
AT (3) ATE430738T1 (pl)
AU (3) AU2004215673B2 (pl)
BR (3) BRPI0407758A (pl)
CA (3) CA2517381A1 (pl)
CL (2) CL2004000391A1 (pl)
CO (2) CO5690578A2 (pl)
DE (4) DE10308355A1 (pl)
DK (3) DK1599452T3 (pl)
EC (2) ECSP055985A (pl)
ES (3) ES2329366T3 (pl)
HR (3) HRP20050742A2 (pl)
IL (2) IL170314A (pl)
MA (3) MA27736A1 (pl)
MX (3) MXPA05008988A (pl)
NO (3) NO20054408L (pl)
OA (2) OA13035A (pl)
PA (1) PA8596801A1 (pl)
PE (3) PE20050292A1 (pl)
PL (3) PL377735A1 (pl)
PT (3) PT1599452E (pl)
RS (1) RS20050594A (pl)
RU (3) RU2005129992A (pl)
SA (1) SA04250153A (pl)
TN (2) TNSN05206A1 (pl)
TW (3) TW200510352A (pl)
UY (2) UY28209A1 (pl)
WO (3) WO2004076428A1 (pl)
ZA (2) ZA200505765B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
AU2009218009B2 (en) 2008-02-29 2013-10-03 Nissan Chemical Industries, Ltd. Process for production of thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116203811B (zh) 2017-12-13 2025-01-21 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
UA64713C2 (uk) 1996-12-31 2004-03-15 Reddys Lab Ltd Dr Похідні азолідиндіону, спосіб їх одержання (варіанти), фармацевтичні композиції на їх основі, спосіб попередження або лікування, спосіб зниження рівня глюкози і проміжна сполука
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002543065A (ja) * 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ES2265952T3 (es) 1999-06-18 2007-03-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y ariloxazolidindiona.
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
MXPA02001696A (es) 1999-09-01 2002-08-06 Aventis Pharma Gmbh Derivados de sulfonilcarboxamida, metodo para su produccion y su uso como medicamentos.
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
ATE261431T1 (de) 1999-12-03 2004-03-15 Astrazeneca Ab Kristalline form von (s)-2-ethoxy-3-4-(2-4- methansulfonyloxyphenyl-ethoxy)phenyl)propansäu e
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
EP1283735B2 (en) 2000-03-31 2012-10-24 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
MXPA02010545A (es) 2000-04-25 2004-05-14 Kyorin Seiyaku Kk Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo.
ES2287120T3 (es) 2000-04-28 2007-12-16 Asahi Kasei Pharma Corporation Nuevos compuestos biciclicos.
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
HUP0301749A2 (hu) 2000-06-09 2003-09-29 Aventis Pharma Deutschland Gmbh. Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
PL360744A1 (pl) * 2000-08-23 2004-09-20 Eli Lilly And Company Pochodne kwasu oksazolilo-arylopropionowego i ichstosowanie jako agonistów PPAR
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CZ20031732A3 (cs) 2000-12-21 2003-09-17 Aventis Pharma Deutschland Gmbh 1,2-Difenylazetidinony a farmaceutické prostředky s jejich obsahem k léčení poruch metabolismu lipidů
BR0116526A (pt) * 2000-12-25 2004-07-06 Ono Pharmaceutical Co Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
ES2275887T3 (es) * 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EP1425014B1 (de) 2001-08-31 2006-12-13 Sanofi-Aventis Deutschland GmbH Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
EP1474385B1 (en) 2002-02-05 2009-06-10 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
US20050215596A1 (en) 2005-09-29
EP1599453B1 (de) 2009-05-06
AR043433A1 (es) 2005-07-27
BRPI0407814A (pt) 2006-02-14
US7872034B2 (en) 2011-01-18
OA13035A (en) 2006-11-10
CN100439345C (zh) 2008-12-03
MXPA05008995A (es) 2005-10-18
ATE365159T1 (de) 2007-07-15
BRPI0407758A (pt) 2006-02-14
ATE435217T1 (de) 2009-07-15
ATE430738T1 (de) 2009-05-15
JP2006519194A (ja) 2006-08-24
US7259177B2 (en) 2007-08-21
EP1599452A1 (de) 2005-11-30
WO2004076426A1 (de) 2004-09-10
PL378437A1 (pl) 2006-04-03
ZA200505765B (en) 2006-05-31
DE502004009690D1 (de) 2009-08-13
ES2326418T3 (es) 2009-10-09
AU2004215673B2 (en) 2009-10-01
NO20054398L (no) 2005-11-02
PL378130A1 (pl) 2006-03-06
US20080015238A1 (en) 2008-01-17
ZA200505768B (en) 2005-11-23
CO5690578A2 (es) 2006-10-31
AR043427A1 (es) 2005-07-27
ES2287700T3 (es) 2007-12-16
PT1599452E (pt) 2007-09-12
IL170314A (en) 2010-11-30
RU2005130002A (ru) 2006-01-27
AU2004215677A1 (en) 2004-09-10
PT1599455E (pt) 2009-09-29
PE20040959A1 (es) 2005-01-17
DE502004004139D1 (de) 2007-08-02
HRP20050742A2 (en) 2006-09-30
CO5690580A2 (es) 2006-10-31
NO20054396D0 (no) 2005-09-22
UY28209A1 (es) 2004-09-30
US20050101637A1 (en) 2005-05-12
DK1599455T3 (da) 2009-11-09
MXPA05008988A (es) 2005-10-18
EP1599453A1 (de) 2005-11-30
NO20054408D0 (no) 2005-09-22
CA2517381A1 (en) 2004-09-10
PT1599453E (pt) 2009-07-14
MXPA05008951A (es) 2005-11-04
NO20054398D0 (no) 2005-09-22
JP2006519193A (ja) 2006-08-24
KR20050105492A (ko) 2005-11-04
WO2004076427A1 (de) 2004-09-10
CL2004000392A1 (es) 2005-04-22
CA2517386A1 (en) 2004-09-10
PE20050293A1 (es) 2005-05-24
CN1756748A (zh) 2006-04-05
MA27736A1 (fr) 2006-02-01
US20080167354A1 (en) 2008-07-10
ECSP055985A (es) 2006-01-16
AU2004215672A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
CN1753879A (zh) 2006-03-29
TW200508210A (en) 2005-03-01
NO20054396L (no) 2005-11-11
EP1599455B1 (de) 2009-07-01
TW200510352A (en) 2005-03-16
KR20050106462A (ko) 2005-11-09
TNSN05206A1 (en) 2007-06-11
US7365084B2 (en) 2008-04-29
TW200500349A (en) 2005-01-01
UY28210A1 (es) 2004-09-30
AU2004215673A1 (en) 2004-09-10
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CL2004000391A1 (es) 2005-01-07
MA27737A1 (fr) 2006-02-01
BRPI0407907A (pt) 2006-02-14
CA2516620A1 (en) 2004-09-10
DE502004009453D1 (de) 2009-06-18
RU2005129995A (ru) 2006-01-27
OA13034A (en) 2006-11-10
TNSN05204A1 (en) 2007-06-11
US7335671B2 (en) 2008-02-26
JP2006519199A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
PE20050292A1 (es) 2005-05-24
DK1599452T3 (da) 2007-10-01
MA27742A1 (fr) 2006-02-01
US20040209920A1 (en) 2004-10-21
ECSP055986A (es) 2006-01-16
CN100398526C (zh) 2008-07-02
SA04250153A (ar) 2005-12-03
EP1599452B1 (de) 2007-06-20
CN1753881A (zh) 2006-03-29
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
KR20050106461A (ko) 2005-11-09
CN100439347C (zh) 2008-12-03
DK1599453T3 (da) 2009-08-24
ES2329366T3 (es) 2009-11-25
PL377735A1 (pl) 2006-02-20
DE10308355A1 (de) 2004-12-23
EP1599455A1 (de) 2005-11-30
RS20050594A (en) 2007-12-31
WO2004076428A1 (de) 2004-09-10
AU2004215672B2 (en) 2010-01-07
AR043432A1 (es) 2005-07-27

Similar Documents

Publication Publication Date Title
HRP20050744A2 (en) 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
HRP20050532A2 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
ATE534650T1 (de) Neue cyanothiazolide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HRP20050711A2 (en) NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-a]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
NO20055892L (no) Karboksylsyrederivater
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2005080324A8 (en) Sulfonamide derivatives for the treatment of diseases
WO2004087686A3 (en) Benzopyran compounds useful for treating inflammatory conditions
JO2449B1 (en) Thiosol derivatives - benziazothiazole dioxide, methods of preparation and use.
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
MA27232A1 (fr) Derives d'acide n-benzoylureidocinnamique, leurs procedes de preparation et leurs utilisations
DK1809288T3 (da) Anvendelse af 1,4-bis-(3-aminoalkyl)piperazinderivater ved behandling af neurodegenerative sygdomme
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
DE502005001315D1 (de) Heterocyclisch substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2003089577A3 (en) Antihelminthic anthraquinones and method of use thereof
CA2654354C (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
HRP20050779A2 (en) Supstituted benzoylureidopyridyl-piperidine and pyrrolidine carboxylic acid derivatives, method for the production thereof and the use thereof
TW200505892A (en) Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn